Discontinue use if interstitial lung disease develops. Not to be initiated if baseline creatine kinase >5 times upper limit of normal. Not be used in patients w/ acute, serious condition suggestive of myopathy or predisposing to renal failure development secondary to rhabdomyolysis eg, sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders or uncontrolled seizures. Patients w/ predisposing factors for myopathy/rhabdomyolysis eg, hypothyroidism, personal or family history of hereditary muscular disorders, previous history of muscular toxicity w/ another HMG-CoA reductase inhibitor or fibrates. DM. Assess renal function during routine follow-up. Perform liver function test prior to & 3 mth following initiation. Asian patients. Alcohol abuse. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended in combination w/ gemfibrozil. Concomitant use w/ certain PIs; ezetimibe, fibrates. History of hepatic disease. Women of childbearing potential should use effective contraception. Not to be used during pregnancy & lactation. Childn <10 yr. Elderly >70 yr.